Cue Biopharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cue Biopharma and other ETFs, options, and stocks.

About CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). 

CEO
Shao Lee Lin
CEOShao Lee Lin
Employees
29
Employees29
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2014
Founded2014
Employees
29
Employees29

CUE Key Statistics

Market cap
106.78M
Market cap106.78M
Price-Earnings ratio
-3.17
Price-Earnings ratio-3.17
Dividend yield
Dividend yield
Average volume
2.53M
Average volume2.53M
High today
$34.75
High today$34.75
Low today
$29.50
Low today$29.50
Open price
$30.23
Open price$30.23
Volume
360.34K
Volume360.34K
52 Week high
$38.00
52 Week high$38.00
52 Week low
$4.97
52 Week low$4.97

Stock Snapshot

The current Cue Biopharma(CUE) stock price is $32.80, with a market capitalization of 106.78M. The stock trades at a price-to-earnings (P/E) ratio of -3.17.

On 2026-05-05, Cue Biopharma(CUE) stock traded between a low of $29.50 and a high of $34.75. Shares are currently priced at $32.80, which is +11.2% above the low and -5.6% below the high.

The Cue Biopharma(CUE)'s current trading volume is 360.34K, compared to an average daily volume of 2.53M.

During the past year, Cue Biopharma(CUE) stock moved between $4.97 at its lowest and $38.00 at its peak.

During the past year, Cue Biopharma(CUE) stock moved between $4.97 at its lowest and $38.00 at its peak.

CUE News

TipRanks 4d
Cue Biopharma licenses Ascendant-221 and raises new capital

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 4d
Why Is Cue Biopharma Stock Up Today?

Cue Biopharma (CUE) stock rocketed higher on Friday after the clinical-stage biopharmaceutical company announced a $30 million private placement. The company ha...

Benzinga 4d
Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?

$30 Million Raise Funds Pipeline Expansion The PIPE, expected to close around May 4, involves pre-funded warrants for up to 2.72 million shares at an effective...

Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?

More CUE News

TipRanks 5d
Cue Biopharma appoints Shao-Lee Lin as CEO

Cue Biopharma (CUE) announced the appointment of Shao-Lee Lin as CEO president and director. Lin will succeed Lucinda Warren, interim president and CEO. Prior t...

TipRanks 5d
Cue Biopharma announces $30M private placement

Cue Biopharma (CUE) announced that it has entered into a securities purchase agreement with certain accredited investors for a private placement for gross proce...

People also own

Based on the portfolios of people who own CUE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.